Vericel Reports Fourth-Quarter and Year-End 2014 Financial Results
March 23, 2015 16:01 ET
|
Vericel Corporation
Total Revenues of $14.7 Million Reported for the Fourth Quarter
Conference Call Today at 4:30pm Eastern Time
CAMBRIDGE, Mass., March 23, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation...
Vericel to Present at Canaccord Genuity and ARM Investor Conferences
March 18, 2015 08:51 ET
|
Vericel Corporation
CAMBRIDGE, Mass., March 18, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and...
Vericel to Host Fourth-Quarter 2014 Earnings Call on March 23, 2015
March 12, 2015 16:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., March 12, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and...
Vericel to Present at 27th Annual ROTH Conference
March 06, 2015 07:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., March 6, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and...
Vericel Completes Patient Enrollment in Phase 2b ixCELL-DCM Clinical Study of Ixmyelocel-T
January 29, 2015 08:45 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Jan. 29, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and...